Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

Trial Profile

Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liver cancer stem cell therapy (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Dec 2013 Status changed from active, no longer recruiting to completed, as reported by a media release from California Stem Cell.
    • 13 Dec 2013 A full data readout is expected early in 2014, according to a media release from Cellular Biomedicine Group.
    • 13 Dec 2013 The final patient has been treated, according to a media release from Cellular Biomedicine Group.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top